sepranolone

Small moleculeexperimental

Isopregnanolone, also known as isoallopregnanolone and epiallopregnanolone, as well as sepranolone, and as 3β-hydroxy-5α-pregnan-20-one or 3β,5α-tetrahydroprogesterone (3β,5α-THP), is an endogenous neurosteroid and a natural 3β-epimer of allopregnanolone. It has been reported to act as a subunit-selective negative allosteric modulator of the GABAA receptor, and antagonizes in animals and humans some but not all of the GABAA receptor-mediated effects of allopregnanolone, such as anesthesia, sedation, and reduced saccadic eye movements, but not learning impairment. Isopregnanolone has no hormonal effects and appears to have no effect on the GABAA receptor by itself; it selectively antagonizes allopregnanolone and does not affect the effects of other types of GABAA receptor positive allosteric modulators such as benzodiazepines or barbiturates. — Wikipedia

Clinical trial activity

3 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Apr 20, 2018 (NCT03697265)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C
Mol. weight
318.5 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • sepranolone

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05434546Phase 2Feb 16, 2022Asarina Pharma, University of Copenhagen
NCT04102995Phase 2Aug 27, 2019Asarina Pharma
NCT03697265Phase 2Apr 20, 2018Asarina Pharma, Ergomed, Keele University
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Asarina PharmaFor profit3312018
ErgomedFor profit1012018
Keele UniversityAcademic/Hospital1012018
University of CopenhagenAcademic/Hospital1012022
4 organizations
Page 1 / 1